Search results
Found 2364 matches for
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
NEW - Home
Welcome to Oxford Vaccine Group
Known Issues
The content listed below is non-accessible for the following reasons:
Study with us
We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.